Evofem Biosciences Amends 8-K/A for Address Correction
Ticker: EVFM · Form: 8-K/A · Filed: Jan 25, 2024 · CIK: 1618835
Complexity: simple
Sentiment: neutral
Topics: administrative, amendment, corporate-governance
TL;DR
**Evofem Biosciences fixed its address on an SEC filing, a minor but important correction for compliance.**
AI Summary
Evofem Biosciences, Inc. filed an amended 8-K/A on January 25, 2024, to correct its principal executive office address. The original 8-K filed on December 21, 2023, listed 12400 High Bluff Drive, Suite 600, San Diego, CA 92130, but the correct address is 7770 Regents Road, Suite 113-618, San Diego, CA 92122. This matters to investors because accurate contact information is crucial for regulatory compliance and investor communication, ensuring they can reach the company for important updates.
Why It Matters
This amendment ensures the company's public records are accurate, which is fundamental for regulatory compliance and reliable communication with shareholders. Inaccurate contact information can signal operational sloppiness or make it difficult for investors to get critical information.
Risk Assessment
Risk Level: low — The filing is an amendment to correct a minor administrative detail (company address) and does not indicate any material operational or financial risk.
Analyst Insight
This filing is purely administrative and does not provide new financial or operational information. Investors should note the corrected address for future correspondence but should not base investment decisions on this amendment alone. It's a non-event for stock price movement.
Key Numbers
- $0.0001 — par value per share (par value of Evofem Biosciences' Common Stock)
Key Players & Entities
- Evofem Biosciences, Inc. (company) — the registrant filing the 8-K/A
- December 21, 2023 (date) — date of the earliest event reported in the original 8-K
- January 25, 2024 (date) — date the 8-K/A was filed
- 12400 High Bluff Drive, Suite 600, San Diego, CA 92130 (address) — incorrect principal executive office address in the original filing
- 7770 Regents Road, Suite 113-618, San Diego, CA 92122 (address) — correct principal executive office address
- 001-36754 (number) — Commission File Number for Evofem Biosciences, Inc.
- Delaware (company) — State of incorporation for Evofem Biosciences, Inc.
- OTCQB (company) — exchange where Evofem Biosciences' Common Stock (EVFM) is registered
FAQ
What was the primary purpose of Evofem Biosciences, Inc.'s 8-K/A filing on January 25, 2024?
The primary purpose of the 8-K/A filing was to amend the original 8-K filed on December 21, 2023, specifically to correct the company's principal executive office address.
What was the incorrect address listed in the original 8-K filing?
The incorrect address listed in the original 8-K filing was 12400 High Bluff Drive, Suite 600, San Diego, CA 92130.
What is the correct principal executive office address for Evofem Biosciences, Inc. as stated in the 8-K/A?
The correct principal executive office address for Evofem Biosciences, Inc. is 7770 Regents Road, Suite 113-618, San Diego, CA 92122.
What is the trading symbol and the exchange where Evofem Biosciences, Inc.'s common stock is registered?
Evofem Biosciences, Inc.'s common stock trades under the symbol EVFM and is registered on the OTCQB exchange.
What was the 'Date of earliest event reported' for the original 8-K that this amendment refers to?
The 'Date of earliest event reported' for the original 8-K was December 21, 2023.
Filing Stats: 624 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-25 16:23:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share EVFM OTCQB Indicate by
Filing Documents
- form8-ka.htm (8-K/A) — 38KB
- 0001493152-24-003751.txt ( ) — 206KB
- evfm-20231221.xsd (EX-101.SCH) — 3KB
- evfm-20231221_lab.xml (EX-101.LAB) — 33KB
- evfm-20231221_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Date: January 25, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer